Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph + Acute Lymphoblastic Leukemia Patients

Michela Ansuinelli, Maria Stefania De Propris, Maria Cristina Puzzolo, Nadia Peragine, Tiziano Quacquarelli, Saveria Capria, Cristina Skert, Valentina Mancini, Simona Sica, Federico Lussana, Erika Borlenghi, Marco Cerrano, Daniele Vallisa, Valeria Cardinali, Sabina Chiaretti, Anna Guarini, Robin Foà

Blood (2024) 144 (Supplement 1): 838.

https://doi.org/10.1182/blood-2024-208827

Published: 2024

Journal Articles

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 2359.

https://doi.org/10.1182/blood-2021-147200

Published: 2021

Journal Articles

Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-139773

Published: 2020

Journal Articles

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Michela Ansuinelli, MD, Antonella Vitale, MD, Giovanna Pecoraro, MD, Saveria Capria, MD, Silvia Maria Trisolini, MD, Clara Minotti, MD, Claudio Cartoni, MD, Anna Maria Testi, MD, Maria Luisa Moleti, MD, Anna Paola Iori, MD, Walter Barberi, MD PhD, Irene Della Starza, PhD, Loredana Elia, Bs, Francesca Mancini, Maria Stefania De Propris, Anna Guarini, PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5121.

https://doi.org/10.1182/blood-2019-128156

Published: 2019

Journal Articles

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Saad Akhtar, MD, Silvia Montoto, MD, Ariane Boumendil, PhD, Luca Castagna, MD, Herve Finel, Tamas Masszi, MD, Pavel Jindra, MD PhD, Damir Nemet, MD PhD, Herrad Baurmann, MD, Yves Beguin, MD PhD, Felicetto Ferrara, Saveria Capria, MD, Ram Malladi, MD PhD, Jose M Moraleda, MD PhD, Gilles Salles, MD PhD, Adrian Bloor, Julia Meissner, MD, Anna Sureda, MD, Peter Dreger, MD

Blood (2016) 128 (22): 514.

https://doi.org/10.1182/blood.V128.22.514.514

Published: 2016

Journal Articles

Novel Agents Versus Conventional Drugs for the Treatment of Relapsed Multiple Myeloma Patients: Experience of a Single Center over the Last 25 Years

Sara Grammatico, Elisabetta Lisi, PhD, Laura Cesini, MD, Maria Letizia Vallone, PhD, Saveria Capria, MD, Robin FoÃ, MD, Maria Teresa Petrucci, MD

Blood (2015) 126 (23): 5385.

https://doi.org/10.1182/blood.V126.23.5385.5385

Published: 2015

Journal Articles

Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL

Blood (2015) 126 (23): 1999.

https://doi.org/10.1182/blood.V126.23.1999.1999

Published: 2015

Journal Articles

Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia

Blood (2014) 124 (21): 1063.

https://doi.org/10.1182/blood.V124.21.1063.1063

Published: 2014

Journal Articles

Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects

Blood (2014) 124 (21): 5326.

https://doi.org/10.1182/blood.V124.21.5326.5326

Published: 2014

Journal Articles

Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia

Blood (2014) 124 (21): 3687.

https://doi.org/10.1182/blood.V124.21.3687.3687

Published: 2014

Journal Articles

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

Giuseppe Visani, Pietro Maria Stefani, Saveria Capria, Lara Malerba, Piero Galieni, Francesco Gaudio, Giorgina Specchia, Giovanna Meloni, Filippo Gherlinzoni, Roberta Gonella, Marco Gobbi, Armando Santoro, Felicetto Ferrara, Marco Rocchi, Enrique M. Ocio, Maria Dolores Caballero, Federica Loscocco, Alessandro Isidori

Blood (2014) 124 (19): 3029–3031.

https://doi.org/10.1182/blood-2014-08-596668

Published: 2014

Journal Articles

Peripheral T-Cell Lymphomas (PTCL) Treated With Or Without Upfront Autologous Stem Cell Transplantation: Results Of a Retrospective Single Center Analysis

Alice Di Rocco, MD, Angelo Fama, MD, Eleonora Russo, MD, Giovanna Meloni, MD, Paolo Paesano, MD, Laura Cesini, MD, Michela Ansuinelli, MD, Saveria Capria, MD, Maurizio Martelli, MD, Robin Foá, MD

Blood (2013) 122 (21): 5548.

https://doi.org/10.1182/blood.V122.21.5548.5548

Published: 2013

Journal Articles

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

Blood (2013) 122 (21): 2134.

https://doi.org/10.1182/blood.V122.21.2134.2134

Published: 2013

Journal Articles

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

Blood (2011) 118 (12): 3419–3425.

https://doi.org/10.1182/blood-2011-04-351924

Published: 2011

Journal Articles

A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients

Giuseppe Visani, Lara Malerba, Pietro Maria Stefani, Saveria Capria, Piero Galieni, Francesco Gaudio, Giorgina Specchia, Giovanna Meloni, MD, Filippo Gherlinzoni, MD, Claudio Giardini, Sadia Falcioni, Federica Loscocco, Francesca Cuberli, Marco Gobbi, MD, Armando Santoro, Barbara Sarina, Marco Rocchi, Alessandro Isidori, MD, PhD

Blood (2010) 116 (21): 31.

https://doi.org/10.1182/blood.V116.21.31.31

Published: 2010

Journal Articles

Prognostic Role of PET-FDG Before Autologous Stem Cell Transplantation in Advanced Hodgkin's Lymphoma.

Alessandro Pulsoni, MD, Elena Cavalieri, Saveria Capria, Fabio Torelli, Giorgia Annechini, Federico De Angelis, Angela Matturro, Livia Santini, Giovanna Meloni, Robin Foà

Blood (2009) 114 (22): 1548.

https://doi.org/10.1182/blood.V114.22.1548.1548

Published: 2009

Journal Articles

Mlecular Monitoring of Acute Myeloid Leukemia Patients Carrying Nucleophosmin ( NPM1 ) Mutations Undergoing An Autologous Peripheral Blood Stem Cell Transplantation

Valentina Gianfelici, Daniela Diverio, Saveria Capria, Silvia maria Trisolini, Sonia Buffolino, Valentina Derme, Attilio di Lascio, Marilisa Marinelli, Simona Santangelo, Brunangelo Falini, Foà Robert, Meloni Giovanna

Blood (2008) 112 (11): 4864.

https://doi.org/10.1182/blood.V112.11.4864.4864

Published: 2008

Journal Articles

Type of Relapse in 91 Newly Diagnosed MM Patients Treated with High Dose Chemotherapy Followed by Autologous Stem Cell Transplantation.

Maria Teresa Petrucci, MD, Giuseppe Avvisati, MD, PhD, Ombretta Annibali, MD, Saveria Capria, MD, Maria S. De Propris, PhD, Patrizia Del Bianco, PhD, Vincenzo Federico, Cristiano Gallucci, MD, Maria Gozzer, MD, Chiara Gregorj, PhD, Annalisa Natale, MD, Azzurra Romeo, MD, Giovanna Meloni, MD, Robert Foa, MD

Blood (2006) 108 (11): 5451.

https://doi.org/10.1182/blood.V108.11.5451.5451

Published: 2006

Journal Articles

Follow-Up of Chronic Lymphocytic Leukemia (CLL) Patients Who Relapse after Autologous Stem Cell Transplantation (ASCT).

Silvia M. Trisolini, MD, Francesca R. Mauro, MD, Saveria Capria, MD, Giuseppe Cimino, MD, Maria S. De Propris, Phd, Anna Proia, MD, Robin Foà, Giovanna Meloni, MD

Blood (2004) 104 (11): 5212.

https://doi.org/10.1182/blood.V104.11.5212.5212

Published: 2004

NARROW

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph + Acute Lymphoblastic Leukemia Patients

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Novel Agents Versus Conventional Drugs for the Treatment of Relapsed Multiple Myeloma Patients: Experience of a Single Center over the Last 25 Years

Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL

Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia

Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects

Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

Peripheral T-Cell Lymphomas (PTCL) Treated With Or Without Upfront Autologous Stem Cell Transplantation: Results Of a Retrospective Single Center Analysis

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients

Prognostic Role of PET-FDG Before Autologous Stem Cell Transplantation in Advanced Hodgkin's Lymphoma.

Mlecular Monitoring of Acute Myeloid Leukemia Patients Carrying Nucleophosmin ( NPM1 ) Mutations Undergoing An Autologous Peripheral Blood Stem Cell Transplantation

Type of Relapse in 91 Newly Diagnosed MM Patients Treated with High Dose Chemotherapy Followed by Autologous Stem Cell Transplantation.

Follow-Up of Chronic Lymphocytic Leukemia (CLL) Patients Who Relapse after Autologous Stem Cell Transplantation (ASCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only